Appln. No.: PCT/US2003/035427 Docket No.: 32.US2.PCT

Preliminary Amendment Dated: May 4, 2005

Page 11 of 11

Remarks

After entry of the above amendment, claims 1-14, 20, 21, and 26-28 will be pending in this application.

Claims 1-13 and 20 have been amended.

Claims 15-19 and 22-25 have been cancelled.

Claims 26-28 have been added.

Support for the amendments and new claims can be found throughout the specification and in the original claims.

It is respectfully submitted that no new matter has been added by way of this amendment. The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16, 1.17, and 1.492 as required by this paper to Deposit Account No. 50-1441.

Respectfully submitted,

Date: _____ May 4, 2005

David L. Bradfute Registration No. 39,117

Arena Pharmaceuticals, Inc. 6166 Nancy Ridge Drive San Diego, CA 92121 Telephone: (858) 453-7200

Facsimile: (858) 677-0065